Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS.

[1]  R. Dorr,et al.  Modulation of mitomycin C-induced multidrug resistance in vitro , 2004, Cancer Chemotherapy and Pharmacology.

[2]  C. Preudhomme,et al.  Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplastic syndromes. , 1998, Leukemia & lymphoma.

[3]  E. Wattel,et al.  Long‐term follow‐up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long‐term survivors and outcome of partial responders , 1997, British journal of haematology.

[4]  E. Wattel,et al.  99 Expression of LRP and its correlation with other drug resistance proteins and outcome in myelodysplastic syndromes (MDS) , 1997 .

[5]  R. Willers,et al.  Remission Rates, Survival, and Prognostic Factors in Ninety Patients with Advanced Myelodysplastic Syndromes Treated with Intensive Chemotherapy , 1997 .

[6]  H. Dombret,et al.  Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia , 1997, Leukemia.

[7]  P. Sonneveld,et al.  Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. , 1996, Leukemia.

[8]  R. Pirker,et al.  Multidrug resistance in leukemias and its reversal. , 1996, Leukemia & lymphoma.

[9]  E. Solary,et al.  Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. , 1996, Blood.

[10]  V. Gekeler,et al.  MDR1, MRP, topoisomerase IIalpha/beta, and cyclin A gene expression in acute and chronic leukemias. , 1996, Leukemia.

[11]  A. Glasmacher,et al.  Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines. , 1996, Leukemia.

[12]  P. Sonneveld.  Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies. , 1996, European journal of cancer.

[13]  A. List,et al.  Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. , 1996, Leukemia.

[14]  D. Hossfeld,et al.  The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives , 1996, Annals of Hematology.

[15]  H. Zwierzina,et al.  Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). , 1995, Leukemia.

[16]  F. Appelbaum,et al.  Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases. , 1995, Blood.

[17]  W. Wilson,et al.  Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  F. Ichas,et al.  Differential effects of verapamil and quinine on the reversal of doxorubicin resistance in a human leukemia cell line , 1995, International journal of cancer.

[19]  J. Merlin,et al.  Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. , 1995, Blood.

[20]  M. Dimopoulos,et al.  VAD-cyclosporine therapy for VAD-resistant multiple myeloma. , 1995, Leukemia & lymphoma.

[21]  B. Quesnel,et al.  p53 Mutations Are Associated With Resistance to Chemotherapy and Short Survival in Hematologic Malignancies , 1994 .

[22]  P. Wood,et al.  P‐glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival , 1994, British journal of haematology.

[23]  C. Preudhomme,et al.  Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. , 1994, Leukemia.

[24]  R. Pirker,et al.  P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. , 1994, Leukemia.

[25]  P. Wigler,et al.  Reversal agent inhibition of the multidrug resistance pump in human leukemic lymphoblasts. , 1994, Biochimica et biophysica acta.

[26]  U. Germing,et al.  Treatment of advanced primary myelodysplastic syndromes with AML-type chemotherapy: Results in 76 patients , 1994 .

[27]  B. Chauffert,et al.  Comparative effects of quinine and cinchonine in reversing multidrug resistance on human leukemic cell line K562/ADM. , 1994, Leukemia.

[28]  A. Miyajima,et al.  Receptors for granulocyte-macrophage colony-stimulating factor, interleukin-3, and interleukin-5 , 1993 .

[29]  A. Duhamel,et al.  Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. , 1993, Leukemia.

[30]  W. Dalton,et al.  Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Magaud,et al.  High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. , 1993, Blood.

[32]  S. McKenna,et al.  MULTIDRUG RESISTANCE IN LEUKAEMIA , 1997, Bailliere's clinical haematology.

[33]  B. Chauffert,et al.  Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  O. Legrand,et al.  Multidrug resistance (MDR) gene expression in acute non lymphoblastic leukemia: sequential analysis. , 1992, Leukemia & lymphoma.

[35]  B. Chauffert,et al.  Cinchonine, a potent efflux inhibitor to circumvent anthracycline resistance in vivo. , 1992, Cancer research.

[36]  T. Tsuruo,et al.  Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. , 1992, Blood.

[37]  B. Chauffert,et al.  Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM , 1991, Cancer.

[38]  B. Chauffert,et al.  P-glycoprotein expression and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukaemia and myeloma. , 1991, Leukemia.

[39]  O. Haas,et al.  MDR1 gene expression and treatment outcome in acute myeloid leukemia. , 1991, Journal of the National Cancer Institute.

[40]  P. Morel,et al.  Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy , 1991, British journal of haematology.

[41]  T. Grogan,et al.  P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  S. Hanada,et al.  Expression of the multidrug transporter, P‐glycoprotein, in acute leukemia cells and correlation to clinical drug resistance , 1990, Cancer.

[43]  C. Haanen,et al.  Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia , 1990, Cancer.

[44]  C. Wolf,et al.  Glutathione-s-transferase pi expression in leukaemia: a comparative analysis with mdr-1 data. , 1990, British Journal of Cancer.

[45]  R. Day,et al.  MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia , 1990, British journal of haematology.

[46]  B. Chauffert,et al.  Quinine circumvents the doxorubicin resistance of a multidrug resistant human leukemic cell-line, K562/DXR. , 1990, Nouvelle revue francaise d'hematologie.

[47]  R. Gray,et al.  AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial , 1989, British journal of haematology.

[48]  P. Martiat,et al.  Intensive chemotherapy for acute non‐lymphoblastic leukemia after primary myelodysplastic syndrome , 1988, Hematological oncology.

[49]  D. Arthur,et al.  Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. , 1985, Blood.